Status:
RECRUITING
Trastuzumab Deruxtecan in Advanced Breast Cancer
Lead Sponsor:
Wenjin Yin
Conditions:
Advanced Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Eligibility Criteria
Inclusion
- Aged ≥18 and older
- Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
- ECOG 0-1
Exclusion
- During pregnancy and lactation
Key Trial Info
Start Date :
August 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2029
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT07180264
Start Date
August 28 2025
End Date
February 1 2029
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127